Showing results (21-30 of 80) with videos related to
Sort By:
Pageof 8
JACC. Advances|February 26, 2026
Frailty Status Predicts Adverse Outcomes in Ambulatory Heart Failure With Preserved Ejection FractionRadu Tanacli, Rishi K Trivedi, Masih Tajdini, et al.The Canadian Journal of Cardiology|February 9, 2020
Management of Cardiac Amyloidosis: Do's and Don'tsKevin M Alexander, Ronald M WittelesJACC. Heart Failure|August 13, 2018
Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine: The ROPA-DOP TrialKavita Sharma, Joban Vaishnav, Rohan Kalathiya, et al.Circulation|October 29, 2020
Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection FractionVirginia S Hahn, Hildur Knutsdottir, Xin Luo, et al.JACC. Cardiooncology|April 22, 2026
Disease Prognosis and Progression in Transthyretin Amyloidosis: JACC: CardioOncology State-of-the-Art ReviewJoban Vaishnav, Dimitrios Bampatsias, Brian C Boursiquot, et al.Cardiology Clinics|October 8, 2019
Diagnosis and Treatment of Cardiac Amyloidosis Related to Plasma Cell DyscrasiasKevin M Alexander, Alessandro Evangelisti, Ronald M WittelesPharmacology & Therapeutics|June 27, 2017
Novel pharmacotherapies for cardiac amyloidosisKevin M Alexander, Avinainder Singh, Rodney H FalkCurrent Treatment Options in Cardiovascular Medicine|July 17, 2019
Emerging Therapies for Transthyretin Cardiac AmyloidosisKevin M Alexander, Alessandro Evangelisti, Ronald M WittelesJACC. Heart Failure|December 2, 2025
Monitoring Disease Progression in Patients With Transthyretin Amyloid CardiomyopathyPablo García-Pavía, Ronald M Witteles, Thibaud Damy, et al.Current Cardiology Reports|January 15, 2020
Harnessing Cardiac Regeneration as a Potential Therapeutic Strategy for AL Cardiac AmyloidosisShaurya Joshi, Alessandro Evangelisti, Ronglih Liao, et al.Pageof 8